CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia  by Passaro, Diana et al.
ArticleCXCR4 Is Required for Leukemia-Initiating Cell
Activity in T Cell Acute Lymphoblastic LeukemiaHighlightsd CXCR4 is required for T-ALL cell migration, homing, and
niche positioning
d CXCR4 surface expression depends upon calcineurin-
dependent expression of cortactin
d CXCR4 is critical to T-ALL cell leukemogenicityPassaro et al., 2015, Cancer Cell 27, 769–779
June 8, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.ccell.2015.05.003Authors
Diana Passaro, Marta Irigoyen, ...,
Christine Tran Quang,
Jacques Ghysdael
Correspondence
diana.passaro@crick.ac.uk (D.P.),
jacques.ghysdael@curie.fr (J.G.)
In Brief
Passaro et al. show that CXCR4 is
important for T cell acute lymphoblastic
leukemia (T-ALL) propagation in vivo and
that calcineurin regulates cortactin-
dependent CXCR4 cell-surface
expression. These results suggest
targeting CXCR4 as a promising
approach for treating T-ALL.
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http://dx.doi.org/10.1016/j.ccell.2015.05.003SUMMARYImpaired cell migration has been demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cells upon
calcineurin inactivation, among other phenotypic traits including increased apoptosis, inhibition of cell pro-
liferation, and ultimately inhibition of leukemia-initiating cell (LIC) activity. Herein we demonstrate that the
chemokine receptor CXCR4 is essential to the LIC activity of T-ALL leukemic cells both in NOTCH-induced
mouse T-ALL and human T-ALL xenograft models. We further demonstrate that calcineurin regulates
CXCR4 cell-surface expression in a cortactin-dependent manner, a mechanism essential to the migratory
properties of T-ALL cells. Because 20%–25% of pediatric and over 50% of adult patients with T-ALL do
not achieve complete remission and relapse, our results call for clinical trials incorporating CXCR4 antago-
nists in T-ALL treatment.INTRODUCTION
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive ma-
lignancy, which results from the leukemic transformation of T cell
progenitors. Despite progress in intensive chemotherapy, 20%–
25%of pediatric and over 50%of adult patients with T-ALL show
resistance to therapy and relapse (Pui et al., 2011). The molecu-
lar genetic bases of T-ALL are well characterized (Van Vlier-
berghe and Ferrando, 2012), yet this knowledge has not trans-
lated into targeted therapies. T-ALL-initiating/propagating cells
(LIC) are thought to be responsible for relapse following chemo-
therapy (Clappier et al., 2011). Available evidence from specific
leukemias, for example chronic myeloid leukemia, indicates
that LIC resistance to treatment involves both deregulation of
intrinsic molecular pathways and response to microenviron-
mental cues (Corbin et al., 2011; Hamilton et al., 2012). The mo-
lecular mechanisms underlying the interactions between T-ALL
cells and their microenvironment are, however, mostly unknown.Significance
T cell acute lymphoblastic leukemia (T-ALL) shows resistance
than half of adult patients. The molecular genetic bases of T-A
have not translated into targeted therapies. More effective th
an essential function of CXCR4 for leukemia propagation in
regulation of CXCR4 cell-surface expression to the calcineurin-
Targeting the calcineurin-CXCR4 axis is a promising approac
chemotherapy regimens in T-ALL.Calcineurin (PPP3) is a serine-threonine protein phosphatase
that we previously showed to be activated in T-ALL (Medyouf
et al., 2007) and identified as essential to LIC activity in T-ALL
mouse models (Gachet et al., 2013; Medyouf et al., 2007). In
somatic tissues, calcineurin is composed of a catalytic subunit,
encoded by two distinct genes (PPP3CA and PPP3CB), and a
regulatory subunit, encoded by PPP3R1. Calcineurin regulates
the physical and functional interaction that T-ALL cells establish
with other cells in the tumor microenvironment, notably their
adhesive and migratory properties (Gachet et al., 2013).
Calcineurin-dependent adhesive and migratory properties
may regulate the ability of leukemic cells to reach their support-
ive stromal niches, dynamically exchange between different
niche compartments, and exit from these niches for further
dissemination.
In this study, we sought to identify a functional link between
calcineurin activity and the response of T-ALL cells to a micro-
environmental signal(s) and to determine whether interruptingto first-line chemotherapy in 20%–25% of children and more
LL emergence and maintenance are well characterized but
erapeutic options thus need to be sought. Here we report
murine and human T-ALL models. Furthermore, we link
dependent expression of the actin-binding protein cortactin.
h to interfere with leukemogenesis and to improve current
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this signal(s) can impinge upon leukemia development, thus
providing alternative strategies for T-ALL treatment.
RESULTS
Calcineurin Inactivation Affects CXCR4 Surface
Expression and CXCL12/CXCR4-Induced T-ALL Cell
Migration
T-ALL induced in mice by an activated allele of NOTCH1 (ICN1)
were generated as previously described (Gachet et al., 2013).
Infusion of these leukemias (ICN1;Rosa-Cre-ERT2 and carrying
either the Ppp3r1fl/fl, Ppp3r1fl/+, Ppp3r1fl/, or Ppp3r1+/+ alleles)
into secondary wild-type hosts resulted in their synchronous
engraftment. Once tumor burden reached over 5%–10% of
bone marrow cells, mice were treated with tamoxifen (Tam) to
induce Cre-mediated Ppp3r1 deletion specifically in leukemic
cells (Figure S1A), which were then retrieved for further analysis.
Control leukemic cells were obtained frommice treated with car-
rier solvent (corn oil) and from tamoxifen-treated mice carrying
Ppp3r1fl/+ and Ppp3r1+/+ T-ALL.
To identify calcineurin-dependent regulators of T-ALL cell
migration, we compared the motility of calcineurin-proficient
(Ppp3r1fl/fl; Ppp3r1fl/) and calcineurin-deficient (Ppp3r1/)
ICN1 leukemic cells in response to chemokines and cytokines
(Figure 1A). Whereas interleukin 2 (IL2), IL7, and vascular endo-
thelial growth factor (VEGF) showed modest activity, CXCL12
strongly induced primary T-ALL cell motility in a calcineurin-
dependent manner (Figure 1A). Besides chemotaxis, CXCL12
triggering of its CXCR4 receptor results in activation of integrin
receptors, which are essential to transmigration of T cells, for
example, across vascular barriers (Shulman et al., 2009). Anal-
ysis of receptor expression showed that CXCR4 as well as the
integrins aLb2 (LFA-1) and a4b1 (VLA-4) were expressed at the
cell surface in a panel of ICN1 T-ALL cells (Figure 1B and data
not shown). We thus tested the ability of calcineurin-deficient
leukemic cells to activate integrin-mediated migration in
response to CXCL12. Interestingly, calcineurin deficiency
impaired integrin-dependent T-ALL cell motility (Figures 1C–
1E; Figures S1B and S1C). We next investigated how calcineurin
deficiency impaired CXCL12-induced T-ALL cell motility. We
found no difference in CXCR4 RNA and protein expression be-
tween calcineurin-proficient and calcineurin-deficient leukemic
cells generated from several independent ICN1 T-ALLs (Figures
S1D and S1E). In contrast, calcineurin deficiency was accompa-
nied by significant reduction in CXCR4 cell-surface expression
(Figure 1F). This reduction is specific to calcineurin inactivation,
because we found no change in CXCR4 surface expression
in leukemic cells obtained from Tam-treated mice carrying
Ppp3r1fl/+ or Ppp3r1+/+ ICN1 T-ALL (Figures S1F and S1G). Of
note, we also found reduction in CCR7 cell-surface expression
(Figure S1H), a receptor reported to be involved in T-ALL infiltra-
tion of the CNS (Buonamici et al., 2009). In contrast, no change
was observed in surface expression of LFA-1 and VLA-4 be-
tween calcineurin-proficient and calcineurin-deficient T-ALL
cells (Figures S1I and S1J), thus excluding a general defect in
protein cell-surface expression in calcineurin-deficient T-ALL
cells.
Steady-state cell-surface expression of CXCR4 results from a
balance between endocytosis, intracellular trafficking, and recy-770 Cancer Cell 27, 769–779, June 8, 2015 ª2015 Elsevier Inc.cling (Grundler et al., 2009; Masztalerz et al., 2007). To
identify the calcineurin-dependent step(s) in CXCR4 dynamics,
we compared CXCR4 endocytosis and recycling between
calcineurin-proficient and calcineurin-deficient T-ALL cells. We
observed no significant difference between calcineurin-profi-
cient and calcineurin-deficient T-ALL cells for CXCR4 internali-
zation in response to CXCL12 (data not shown). To study
CXCR4 recycling, we first stimulated calcineurin-proficient and
calcineurin-deficient leukemic cells with CXCL12. After 18 hr,
CXCL12 was washed out and cells were examined for the ki-
netics of surface CXCR4 reappearance, as previously described
(Kumar et al., 2011). We observed a severe delay in CXCR4 recy-
cling in calcineurin-deficient cells (Figure 1G). Thus, calcineurin
inactivation affects CXCR4 trafficking and CXCL12/CXCR4-
dependent T-ALL cell migration.
CXCR4 Cell-Surface Restoration in Calcineurin-
Deficient T-ALL Cells Corrects Their Migration Defect
To directly link the motility defect seen in calcineurin-deficient
T-ALL cells to reduction of CXCR4 surface expression, we
sought to restore normal cell-surface expression levels of
CXCR4 in calcineurin-deficient leukemic cells to investigate
whether this would suffice to correct their motility defect. We
transduced ICN1 leukemic cells to express either GFP alone or
coexpress CXCR4 and GFP, and injected transduced cells in
recipient mice, as schematized in Figure 2A. This procedure re-
sulted in the synchronous engraftment of leukemic cells in recip-
ient mice. Once recipients became leukemic, we divided each
group in two: the first was treated with solvent and the second
was treated with Tam, thus generating calcineurin-proficient
(Ppp3r1fl/fl) and calcineurin-deficient (Ppp3r1/) T-ALL cells
that expressed or not exogenous CXCR4 (Figure 2A). No differ-
ence in leukemic load was observed among the four groups
(Figure S2A).We observed increased surface CXCR4 expression
in Ppp3r1fl/fl and Ppp3r1/ T-ALL cells transduced with the
CXCR4-expressing vector as compared to their respective
controls (Figure 2B). Of note, surface CXCR4 expression in
Ppp3r1/ + CXCR4 leukemic cells was reduced as compared
to Ppp3r1fl/fl + CXCR4 leukemic cells, showing that defective
CXCR4 trafficking remains calcineurin-dependent in T-ALL cells
overexpressing CXCR4. Interestingly, enforced CXCR4 expres-
sion in calcineurin-deficient leukemic cells resulted in its expres-
sion at the cell surface at a level similar to that of calcineurin-
proficient cells, thus enabling us to assess CXCR4 function in
otherwise calcineurin-deficient cells (Figure 2B). Restoring sur-
face CXCR4 expression in Ppp3r1/ cells to that of calci-
neurin-proficient (Ppp3r1fl/fl) cells (Figure 2B) rescued themotility
defect of Ppp3r1/ leukemic cells (Figure S2B) and corrected
their migratory defect (Figures 2C and 2D).
Besides cell migration, calcineurin deficiency in T-ALL cells
impairs LIC activity (Gachet et al., 2013). However, restoring
CXCR4 expression in calcineurin-deficient T-ALL cells failed to
correct their proliferation defect (Figures S2C and S2D) and their
inability to propagate leukemia when transplanted to recipient
mice (Figures S2E and S2F; Table S1). Taken together, these
results identify a role for CXCR4 downstream of calcineurin in
T-ALL cell motility and migration and suggest that the other phe-
notypes associated with calcineurin deficiency also rely upon
other calcineurin-dependent molecular targets.
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Figure 1. CXCR4 Cell-Surface Expression and CXCL12-Induced Migration Are Regulated by Calcineurin
(A) Mice carrying ICN1;RCT2;Ppp3r1fl/;BCL-2 leukemia (T-ALL 204) were treated with control solvent (corn oil; So) or tamoxifen to induce Cre-ERT2-mediated
deletion of Ppp3r1. Five days after treatment, the resulting ICN1;Ppp3r1fl/ and ICN1;Ppp3r1/ leukemic cells were sorted and seeded in Boyden chambers to
monitor their motility in response to chemoattractants after 3 hr. Data (n = 3) are represented as fold-motility induction relative to cells migrating toward plain
medium. Data are represented as mean ± SEM (***p < 0.001, **p < 0.01, *p < 0.05; ns, not significant; Student’s t test). IGF, insulin growth factor 1.
(B) ICN1;RCT2;Ppp3r1fl/ leukemic cells were analyzed by flow cytometry for surface expression of CXCR4, LFA-1, and VLA-4. Similar results were obtained with
three other independent ICN1 leukemias (not shown).
(C) Same as in (A), except the chambers were precoated with either ICAM-1 or VCAM-1, the respective ligands of LFA-1 and VLA-4.
(D) Flow cytometry-sorted ICN1;Ppp3r1fl/;BCL-2 or ICN1;Ppp3r1/;BCL-2 leukemic cells obtained as in (A) were seeded on ICAM-1-coated coverslips and
stimulated with CXCL12. Migration of individual cells (n = 20) was recorded for 15 min by time-lapse video microscopy. In the flower plot diagram, the starting
point of each track is placed at the axis origin.
(E) Migration velocity of leukemic cells of the indicated genotypes analyzed in (D) and in Figure S1C. Bars represent mean velocity values (***p < 0.001).
(F) ICN1;Ppp3r1fl/fl T-ALL cells obtained as in (A) were analyzed for CXCR4 surface expression. Right: median fluorescence intensity (MFI) quantification of
CXCR4 expression in independent ICN1;Ppp3r1fl/ or ICN1;Ppp3r1fl/fl leukemias treated with So or Tam. Data are represented as mean ± SEM (n = 8; **p < 0.01).
(G) Cultured ICN1;Ppp3r1fl/fl;BCL-2 leukemic cells treated with 4-hydroxytamoxifen (4OHT) to induce calcineurin inactivation or control solvent were stimulated
with 100 ng/ml CXCL12 for 18 hr, washed, and cultivated without CXCL12 for the indicated time periods. CXCR4 surface expression (MFI) was measured by flow
cytometry. Data are shown as fold increase as compared to stimulated cells (n = 6; ***p < 0.001, **p < 0.01).
See also Figure S1.
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Figure 2. Restoring Normal CXCR4 Surface
Expression in Calcineurin-Deficient T-ALL
Cells Rescues Their Migration Defect
(A) ICN1;RCT2;Ppp3r1fl/fl;BCL-2 (T-ALL 3) leukemic
cells transduced with either an MSCV-IRES-GFP
retrovirus encoding both GFP and murine CXCR4 or
the control retrovirus encoding GFP alone were
sorted according to their positivity for GFP and
intravenously (i.v.) injected into syngeneic mice.
When leukemic load reached about 5% in bone
marrow, mice were treated with either tamoxifen or
solvent followed by their sacrifice 5 days later to
retrieve the leukemic cells of the indicated geno-
types.
(B) Leukemic cells generated in (A) were analyzed
for CXCR4 surface expression by flow cytometry
(left panel). Right: MFI quantification obtained for
independent mice of each group. Data are repre-
sented as mean ± SEM (n = 3; **p < 0.01; ns, not
significant; Student’s t test).
(C) Leukemic cells generated in (A) were flow cy-
tometry sorted and seeded on MS5 stromal cells
and, 18 hr later, migration of individual leukemic
cells (n = 20) was recorded by time-lapse video
microscopy. Data are representative of three indi-
vidual experiments, using two independent ICN1
T-ALLs.
(D) Quantification of the velocity of leukemic cells
analyzed in (C) (***p < 0.001; ns, not significant;
Student’s t test). Bars represent mean velocity.
See also Figure S2 and Table S1.Cortactin Downregulation Is Implicated in theReduction
of CXCR4 Surface Expression in Calcineurin-Deficient
T-ALL Cells
To gain insight into the molecular mechanism underlying defec-
tive CXCR4 trafficking in calcineurin-deficient leukemic cells,
we analyzed the calcineurin-dependent transcriptome of ICN1
T-ALL cells (Gachet et al., 2013; Gene Expression Omnibus
accession numberGSE60258) for deregulation of genes involved
in receptor recycling. We noticed downregulation of cortactin
expression in calcineurin-deficient as compared to calcineurin-
proficient T-ALL cells (fold change 1.87; *p = 4.753 102; Fig-
ure 3A), which was confirmed in independent experiments at the
RNA (Figure 3B) and protein levels (Figure S3A). Cortactin is an
actin-binding protein involved in cytoskeleton dynamic pro-
cesses and has been reported to regulate CXCL12 response of772 Cancer Cell 27, 769–779, June 8, 2015 ª2015 Elsevier Inc.epithelial cells overexpressing CXCR4
(Cosen-Binker and Kapus, 2006; Luo
et al., 2006). We thus investigated whether
reduction of surface CXCR4 expression in
calcineurin-deficient T-ALL cells was a
consequence of cortactin downregulation.
For this, we generated calcineurin-profi-
cient and calcineurin-deficient T-ALL cells
overexpressing exogenous cortactin (Fig-
ure 3C; Figure S3B) and compared cell-
surface expression of CXCR4 and the
migratory properties of these cells. We
found that enforced cortactin expression
in Ppp3r1/ leukemic cells both restored
CXCR4 surface expression to levels similar to those of Ppp3r1fl/fl
T-ALL cells (Figure 3D) and corrected the migratory defect of
calcineurin-deficient cells (Figure 3E). In contrast, enforced
expression of cortactin did not significantly modify either
CXCR4 cell-surface expression or CXCL12-induced migration
of calcineurin-proficient leukemic cells (Figures 3D and 3E).
Thus, calcineurin-dependent regulation of cortactin expression
impinges upon CXCR4 trafficking and on T-ALL cell migration.
CXCR4 Regulates Multiple Phenotypic Traits in T-ALL
To further investigate the importance of CXCR4 in T-ALL, we
transduced ICN1 T-ALL cells to express either GFP (control) or
to coexpress GFP and a CXCR4-specific small hairpin RNA
(shRNA) that efficiently silences CXCR4 expression (Figures 4A
and 4B). CXCR4 silencing inhibited CXCL12-induced motility
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Figure 3. Cortactin Downregulation Is
Implicated in the Reduction of CXCR4 Sur-
face Expression in Calcineurin-Deficient
T-ALL Cells
(A) Microarray analysis of the calcineurin-profi-
cient and calcineurin-deficient versions of five
independent ICN1 T-ALLs was performed as
described (Gachet et al., 2013). Data for the
1423917_a_at probeset corresponding to Cttn,
encoding cortactin, were extracted from the hier-
archical clustering analysis.
(B) Flow cytometry-sorted ICN1;Ppp3r1fl/ and
ICN1;Ppp3r1/ T-ALL cells were analyzed by RT-
PCR for cortactin mRNA expression. b-actin was
used as loading control. Middle and right: Cor-
tactin mRNA quantification normalized to b-actin,
depicted as fold over the control. Data are repre-
sented as mean ± SEM (middle: n = 8 for T-ALL
206; right: n = 4 for T-ALL 3; ***p < 0.001; Student’s
t test).
(C) ICN1;RCT2;Ppp3r1fl/fl;BCL-2 (T-ALL 3)
leukemic cells transduced with either an MSCV-
IRES-GFP retrovirus encoding both GFP and
cortactin or the control retrovirus encoding GFP
alone were sorted according to their positivity for
GFP and injected into syngeneic mice. When
leukemic load reached about 5% in bone marrow,
mice were treated with either tamoxifen or solvent
followed by their sacrifice 5 days later to retrieve
the leukemic cells of the indicated genotypes.
(D) Leukemic cells generated in (C) were analyzed
for CXCR4 surface expression by flow cytometry.
(E) Migration velocity of leukemic cells of the
indicated genotypes seeded on MS5 cells. Bars
represent mean velocity (**p < 0.01; ns, not sig-
nificant; Student’s t test).
See also Figure S3.and transmigratory properties of T-ALL cells (Figure 4C). More-
over, we observed that CXCR4 silencing also inhibited the
expansion of leukemic cells cocultured with MS5 cells (Fig-
ure 4D), due to increased cell death (Figure 4E) and altered
cell-cycle progression (Figure 4F). Taken together, these results
indicate that CXCR4 silencing impinges on several properties of
T-ALL cells in vitro.
We next analyzed the effect of CXCR4 silencing on the in vivo
behavior of T-ALL cells, studying their homing and LIC activity
(Figure 5A). For this, we injected flow cytometry-sorted GFP+
CXCR4-silenced or control leukemic cells in recipient syngeneic
mice and analyzed their homing potential after 24 hr. We
observed a significant reduction of homed leukemic cells in
CXCR4-silenced T-ALL as compared to control (Figure 5B).
We also noticed decreased viability of CXCR4-silenced leukemic
cells in bone marrow compared to control (Figure 5C). Interest-
ingly, intravital two-photon microscopy analysis showed that
CXCR4-silenced cells localized more distantly from the bone
surface as compared to control leukemic cells (Figures 5D andCancer Cell 27, 769–5E). These data suggest that interfering
with CXCR4 expression induces a strong
defect in the interaction/response of
T-ALL cells to stroma-derived signals.We next analyzed the LIC potential of CXCR4-silenced and
control ICN1 leukemic cells by injecting them in recipient mice
under limiting dilution conditions and comparing leukemia devel-
opment in these recipients. As expected, control leukemic cells
induced a fatal leukemia within 17 days in all recipients (LIC fre-
quency 1/415). In contrast, leukemia propagation was abrogated
in two out of sixmice and delayed in the remaining four recipients
injected with CXCR4-silenced cells (Figure 5F; Table 1). Impor-
tantly, whereas infused cells (GFP+) showed efficient CXCR4
knockdown (Figure 5G), leukemic cells retrieved from the four
delayed leukemiasweremostly GFP (Figure 5H) and had recov-
ered CXCR4 cell-surface expression (Figure 5G). These delayed
T-ALLs thus originated from the outgrowth of a minor population
of leukemic cells in which CXCR4 expression was inefficiently
silenced. The antileukemic effect linked to CXCR4 silencing
was suppressed by prior transduction of T-ALL cells with an
exogenous CXCR4 cDNA mutated to render it insensitive to
the inhibitory effects of the shRNA, thus excluding off-target ef-
fects of the shRNA used (Figures 5F, 5H, and 5I; Table 1).779, June 8, 2015 ª2015 Elsevier Inc. 773
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Figure 4. CXCR4 Is Required for ICN1 T-ALL
Cell Motility, Survival, and Proliferation
(A) Schematic representation of the experiment.
ICN1;RCT2;Ppp3r1fl/fl leukemic cells (tNGFR+)
transduced with a TRIP-MND-GFP lentivirus car-
rying a specific shRNA targeting CXCR4 or the
control lentivirus encoding GFP alone were sorted
according to their GFP expression status and
either cocultured with MS5 cells or injected into
syngeneic recipient mice.
(B and C) Cocultured leukemic cells were analyzed
for CXCR4 cell-surface expression by flow cy-
tometry (B) or their ability to migrate in response to
CXCL12 using Boyden chambers in the absence
or through an MS5 cell layer (C). Data (n = 3) are
represented as mean ± SEM fold induction of
migration as compared to leukemic cells migrating
toward plain medium (***p < 0.001; Student’s
t test).
(D) Expansion of control and CXCR4-silenced
leukemic cells was monitored. Data are repre-
sented as mean ± SEM (n = 3; ***p < 0.001; Stu-
dent’s t test).
(E and F) Leukemic cells transduced as described
in (A) were flow cytometry sorted and grown in
coculture with MS5 for 48 hr. At this time, their
apoptotic rate was analyzed by cleaved caspase
3-positive cell detection (data are represented as
mean ± SEM; n = 3; *p < 0.05; Student’s t test) (E)
and their distribution in the sub-G1, G1, S, and G2/
M phases by 7-aminoactinomycin D staining/bro-
modeoxyuridine (BrdU) pulse labeling (data are
represented as mean ± SEM; n = 3; ***p = 0.001;
ns, not significant; Student’s t test) (F).CXCR4 Is Required for Human T-ALL Leukemogenicity
To extend these observations to human T-ALL, we first
silenced CXCR4 in human Jurkat T-ALL cells using two distinct
shRNAs (Yu et al., 2012) (Figures 6A and 6B; Figure S4A) and
analyzed their in vitro and in vivo phenotypes. We found that774 Cancer Cell 27, 769–779, June 8, 2015 ª2015 Elsevier Inc.CXCR4 silencing inhibited Jurkat cell
migration and proliferation while
increasing apoptosis (Figures 6C–6E;
Figures S4B–S4D). This effect was sup-
pressed by prior transduction of Jurkat
cells with an exogenous murine CXCR4
cDNA insensitive to the inhibitory effects
of the shRNA, thus excluding off-target
effects (Figures 6B–6E). CXCR4 silencing
also impaired leukemogenicity of Jurkat
cells xenotransplanted to NSG recipient
mice (Figure S4E). Of note, similar to
what we observed for ICN1 T-ALL,
the delayed leukemias recovered from
mice injected with CXCR4-silenced
cells showed strong counterselection of
shRNA-expressing leukemic cells (Fig-
ures S4F and S4G). To further investi-
gate CXCR4 importance in human
T-ALL, we used xenografts of a human
T-ALL diagnostic sample (M106; Uzanet al., 2014). Following the same experimental strategy (Fig-
ure 6A), leukemic cells were transduced with control or
shCXCR4 vectors, which resulted in decreased CXCR4 cell-
surface expression (Figure 6F), and transduced cells were
injected into NSG recipient mice under limiting dilution
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Figure 5. CXCR4 Is Required for T-ALL Homing and Engraftment In Vivo
(A) Schematic representation of the experiment. ICN1;RCT2;Ppp3r1fl/fl;BCL-2 (T-ALL 3) leukemic cells transduced with either a TRIP-MND-GFP lentiviral vector
encoding an shRNA specific to mouse CXCR4 or the control lentivirus were flow cytometry sorted according to their positivity for GFP and analyzed for their
homing properties and ability to propagate T-ALL following their injection into syngeneic mice.
(B) Homing of leukemic cells to the bone marrow was assessed by flow cytometry 24 hr after intravenous injection. Data are shown as mean ± SEM (n = 3; **p <
0.01; Student’s t test).
(C) Analysis of the percentage of dead (40,6-diamidino-2-phenylindole-positive) cells among GFP+ homed leukemic cells in bone marrow. Data are shown as
mean ± SEM (n = 3; *p < 0.05; Student’s t test).
(D) Intravital measurement of the distances of control and CXCR4-silenced leukemic cells relative to bone and vessel surfaces. Bars represent mean ± SEM (n =
30; ***p < 0.001; Student’s t test).
(E) Distances from the bone surface of control (blue diamonds) and CXCR4-silenced (green circles) leukemic cells are plotted as a function of their distances from
the vessel surface.
(F) ICN1;RCT2;Ppp3r1fl/fl leukemic cells transduced as indicated in (A) were flow cytometry sorted and infused by intravenous inoculation into groups of syngeneic
mice under limiting dilution, as indicated in Table 1. Mice were sacrificed when terminally ill or at day 60, the endpoint of the experiment (see Table 1). Comparison
of the survival of mice infused either with control (blue line) or CXCR4-silenced ICN1;RCT2;Ppp3r1fl/fl T-ALL cells (green line) is shown (n = 3–6; **p < 0.01; log-rank
test). The orange and light blue lines represent, respectively, control and CXCR4-silenced ICN1;RCT2;Ppp3r1fl/fl leukemic cells expressing a CXCR4mutant cDNA
resistant to the inhibitory effects of the shRNA used.
(G–I) Leukemias retrieved from mice in (F) were analyzed by flow cytometry for CXCR4 cell-surface expression (G and I) (MFI is shown; ***p < 0.001; ns, not
significant; Student’s t test) and GFP expression (H) (**p < 0.01; ns, not significant; Student’s t test) (see also Table 1). Bars represent mean ± SEM.
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Table 1. CXCR4 Is Required for T-ALL LIC Activity In Vivo
Leukemia ID
Number
Number of
Inoculated
Cells
Number of
Infused Mice
Number of Engrafted
Mice (Time to Death
[Days])
Day of Sacrifice
(Number of Mice)
Leukemic Cells ±
SEM (BM) (%)
GFP+ Cells among
Leukemic Cells ±
SEM (BM) (%)
Leukemic
Cells ± SEM
(Spleen) (%)
3 empty 104 3 3/3 (17, 17, 17) NA 61 ± 5.62 89.23 ± 1.71 9.3 ± 3.1
shCXCR4 104 6 5/6 (17, 18, 19, 26, 38) 60 (1/6) 51.98 ± 6.98 12.08 ± 9.06 11.8 ± 5.06
empty 103 3 3/3 (17, 17, 17) NA 57.57 ± 5.63 83.48 ± 1.18 7.18 ± 6.26
shCXCR4 103 6 4/6 (18, 19, 22, 22) 60 (2/6) 63 ± 7.55 15.08 ± 9.6 9.08 ± 3.9
empty 102 3 0/3 60 (3/3) 0.69 ± 0.19 0.07 ± 0.03 0.53 ± 0.19
shCXCR4 102 6 0/6 60 (6/6) 0.38 ± 0.24 0.14 ± 0.06 0.44 ± 0.26
3 mutCXCR4 empty 104 4 4/4 (14, 14, 16, 17) NA 60.15 ± 6.56 94.01 ± 3.7 15.7 ± 5.1
shCXCR4 104 4 4/4 (13, 13, 17, 19) NA 51.53 ± 10.5 95.07 ± 2.9 11.4 ± 3.58
empty 103 4 4/4 (16, 16, 16, 17) NA 50.48 ± 10.75 88.95 ± 10.1 9.16 ± 2.9
shCXCR4 103 4 4/4 (13, 17, 17, 17) NA 48.53 ± 7.27 76.9 ± 15.4 8.18 ± 2.91
empty 102 4 0/4 60 (4/4) 0.41 ± 0.21 0.03 ± 0.13 0.35 ± 0.11
shCXCR4 102 4 0/4 60 (4/4) 0.81 ± 0.04 0.11 ± 0.03 0.64 ± 0.29
BM, bone marrow; NA, not applicable.conditions. Mice were followed for leukemia engraftment and
survival. Whereas control leukemic cells gradually accumulated
in the blood and bone marrow of recipient mice, CXCR4
silencing severely inhibited leukemia engraftment (Figures 6G
and 6H). This translated into increased survival of mice injected
with CXCR4-silenced T-ALL cells as compared to control
(Figure 6I). Similar results were obtained using an aggressive
subclone of this human xenotransplanted leukemia (Figures
S4H–S4J). Of note, prior transduction of these cells with an
exogenous mouse CXCR4 cDNA rescued the engraftment
defect of CXCR4-silenced T-ALL cells (Figures S4H–S4J).
These results show that CXCR4 is critical to in vivo propagation
of human T-ALL cells.
DISCUSSION
Calcineurin inactivation impairs T-ALL cell survival and prolifer-
ative and migratory responses to supportive stromal cells
ex vivo and migration across different cellular barriers and leu-
kemia-initiating/propagating cell activity in vivo (Gachet et al.,
2013). We show here that impaired CXCR4 trafficking is central
to defective chemotaxis and migration of calcineurin-deficient
T-ALL cells, and link CXCR4 recycling to calcineurin-dependent
expression of cortactin, a scaffold protein that binds actin and
proteins involved in actin polymerization (Buday and Down-
ward, 2007). Because actin polymerization is required for
CXCR4 trafficking to recycling endosomal vesicles in T cells
(Kumar et al., 2011), inhibition of cortactin expression in calci-
neurin-deficient T-ALL cells likely results in impaired actin dy-
namics in this endosomal compartment. It is worth noting that
overexpression of cortactin has recently been associated with
other parameters of poor prognosis in patients suffering from
B cell chronic lymphocytic leukemia (Gattazzo et al., 2014).
Our data reveal a possible mechanism by which cortactin
expression promotes CXCL12/CXCR4 signaling and thus
leukemic cell migration. However, CXCR4 trafficking deregula-
tion and the resulting migratory defect are not the only conse-
quences of calcineurin inactivation (Gachet et al., 2013). Our776 Cancer Cell 27, 769–779, June 8, 2015 ª2015 Elsevier Inc.results show that restoring CXCR4 expression in calcineurin-
deficient T-ALL cells failed to correct their LIC activity defect,
highlighting the complexity and multitarget function of calci-
neurin in T-ALL.
Further investigation of the intrinsic function of CXCR4 in
T-ALL revealed that, besides chemotaxis and migration,
CXCR4 silencing also impairs survival and proliferation of mu-
rine and human T-ALL cells in vitro, consistent with a direct
supportive function of CXCL12/CXCR4 signaling. This trans-
lates in vivo in the defective homing of CXCR4-deficient
leukemic cells and abnormal positioning of T-ALL cells in the
bone marrow niche, likely resulting in defective interactions
with stromal cells. This ultimately results in the inability of
CXCR4-silenced leukemic cells to survive and efficiently
engraft. Thus, our data strongly support the notion that
CXCL12-producing cells are part of the T-ALL leukemic niche.
Bone marrow expression of CXCL12 has been found in perivas-
cular cells, endothelial cells, and osteoblasts, each having
distinct functions in retention, maintenance, and differentiation
of normal hematopoietic stem/progenitor cells (Ding and Morri-
son, 2013; Greenbaum et al., 2013; Me´ndez-Ferrer et al., 2010).
Our results imply that at least one of these cell types is also crit-
ical to T-ALL LIC activity.
Identification of factors that contribute to microenvironment-
mediated chemoresistance remains an important challenge
for the eradication of residual chemosensitive leukemic blasts
hiding in bone marrow niches (Konopleva and Jordan, 2011).
Several small molecular inhibitors or antibodies are being
developed for CXCL12/CXCR4-targeted therapies (Kuhne
et al., 2013 and references therein). Given the genetic kinship
between the T-ALL clones found in patients at relapse and
those responsible for LIC activity following transplantation in
mice (Clappier et al., 2011), our results and the preclinical activ-
ity of CXCR4 inhibitors in T-ALL xenotransplantation models re-
ported in the accompanying manuscript in this issue of Cancer
Cell (Pitt et al., 2015) call for clinical trials using these agents
either as single treatment or in combination therapy to prevent
T-ALL relapse.
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Figure 6. CXCR4 Is Essential to the Migration, Survival, Proliferation, and Leukemogenicity of Human T-ALL Leukemic Cells
(A) Schematic representation of the experiment. Human Jurkat T-ALL cells or T-ALL xenografts were transduced with a TRIP-MND-GFP lentivirus encoding
shRNAs for human CXCR4 (sh1, sh2) or the same vector without insert and flow cytometry sorted according to GFP expression. GFP+ cells were either cultured
in vitro or injected into NSG mice.
(B) Flow cytometry analysis of CXCR4 surface expression in control (blue line) or CXCR4-silenced Jurkat T-ALL cells (sh2; green line). The orange and light blue
lines represent, respectively, control and CXCR4-silenced Jurkat T-ALL cells expressing amurine CXCR4 cDNA, which resists the inhibitory effects of the shRNA
used.
(C) Leukemic cells shown in (B) were analyzed for their ability to migrate toward CXCL12 using Boyden chambers. Data are represented as fold migration relative
to control cell migration set to 1. Bars represent mean ± SEM (n = 3; ***p < 0.001; ns, not significant; Student’s t test).
(D and E) The same leukemic cells were analyzed for apoptosis by the presence of cleaved caspase 3 (D) (bars represent mean ± SEM; n = 3; ***p < 0.001; ns,
not significant; Student’s t test) and proliferation by BrdU incorporation (E) (bars represent mean ± SEM; n = 3; ***p = 0.001; ns, not significant; Student’s
t test).
(F) Flow cytometry analysis of CXCR4 surface expression in control (blue line) and CXCR4-silenced M106 patient-derived T-ALL cells (sh2; green line).
(legend continued on next page)
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EXPERIMENTAL PROCEDURES
T-ALL Mouse Models
T-ALL induced by an activated allele of NOTCH1 (ICN1) and carrying Cre-delet-
able alleles of PPP3R1 (Ppp3r1) was described previously (see Supplemental
Experimental Procedures). To limit Cre-mediated Ppp3r1 deletion to leukemic
cells, we intravenously infused T-ALL cells of the indicated genotypes into
wild-type syngeneic mice, a procedure that results in synchronous leukemic
engraftment of these recipients. We administered tamoxifen (Sigma-Aldrich;
1 mg/mouse twice at 24-hr intervals) when leukemic burden reached 5%–
10% T-ALL cells in the bone marrow of these recipients. Carrier solvent (corn
oil) was used as control. We sacrificed the mice 5–7 days later, a procedure
that insures efficient deletion of Ppp3r1 and calcineurin inactivation in T-ALL
cells (Gachet et al., 2013). As previously described, in vivo inactivation of calci-
neurin showed no antileukemic activity in bulk leukemic cells (Gachet et al.,
2013). Where indicated, we used ICN1-induced T-ALL expressing an exoge-
nousBcl-2gene inorder tobypass theapoptoticphenotype linked tocalcineurin
inactivation when it comes for these leukemic cells to interact with stromal cells
(Gachet et al., 2013). NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (2 months
old; Charles River Laboratories) were intravenously injected with Jurkat cells
(5 3 106 cells/mouse) or a primary xenograft of T-ALL M106 (a generous gift
of F. Pflumio; Uzan et al., 2014) or M106 T-ALL cells serially passaged in NSG
mice. Mice were injected with 103 leukemic cells/mouse. The phenotypic and
oncogenetic characteristics of T-ALL M106 have been described (Uzan et al.,
2014; Gachet et al., 2013). Mice were maintained under specific pathogen-
free conditions in the animal facility of the Institut Curie, and NSG mice were
maintainedunder constant antibiotic treatment (0.01%Baytril in drinkingwater).
Experimentswere carried out in accordancewith the EuropeanCommunity (86/
609/EEC) and French National Committee (87/848) under agreement number
C91-471-108 delivered by the French Ministry of Agriculture.
Time-Lapse Video Microscopy
For migration assays of T-ALL cells cocultured with MS5 stromal cells, we
seeded MS5 cells on 12-well dishes (BD Biosciences) to obtain a confluent
monolayer 24 hr later. We seeded flow cytometry-sorted ICN1 T-ALL cells
(5 3 105 cells/well) on these monolayers and cocultured the cells overnight.
For video microscopy, we generated phase-contrast images every 10 s for
15 min at 37C. Frame-by-frame displacements and velocities of 20–40
randomly selected leukemic cell movements were calculated by manually
tracking individual cells for 15 min using ImageJ software (NIH) on manual
tracking mode. For migration assays on ICAM-1, we coated 14-mm culture
glasses with recombinant murine ICAM-1 (5 mg/ml ICAM-1/CD54 Fc chimera;
R&D Systems) and seeded flow cytometry-sorted leukemic cells on 12-well
plates carrying ICAM-1-precoated glasses in RPMI supplemented with 5%
fetal bovine serum and 100 ng/ml mouse CXCL12 (PeproTech). After 2 hr,
time-lapse video microscopy was performed as described above.
Homing Assays In Vivo, Confocal Two-Photon Microscopy, and
Image Analysis
GFP+ leukemic cells were transplanted intravenously into syngeneic recipient
mice 24 hr before imaging. Immediately prior to imaging, Alexa Fluor 595-con-
jugated isolectin B4 (Invitrogen) was intravenously injected to label endothelial
cells. Bone was visualized through second-harmonic generation (Lassailly
et al., 2013). Mice were anesthetized with 2.5% isoflurane, and the tops of
the heads were shaved and held in a stereotaxic skull holder. A skin incision
revealed the calvaria, and methylcellulose (4%; Sigma-Aldrich) was applied
to prevent the tissue from drying out. Images were obtained on a Zeiss 710
NLO laser scanning multiphoton microscope with a 203 1.0 NA water immer-
sion lens. Each 10-min z stack of images was rendered in three dimensions
using Imaris software (Bitplane). To measure distances, an isosurface was(G and H) Comparison of human leukemic cell (hCD45+) engraftment in blood (G
silencedM106 patient-derived T-ALL cells and sacrificed at the indicated time poin
significant; Student’s t test).
(I) Kaplan-Meier survival curves of NSGmice xenotransplanted with control or CXC
rank test).
See also Figure S4.
778 Cancer Cell 27, 769–779, June 8, 2015 ª2015 Elsevier Inc.generated for bone and vessels, and the spot function was used to identify
cells of interest. The distance between the center of the cell and the closest
pixel of vessel and bone surfaces was calculated using the distance transfor-
mation algorithm of Imaris XT extension (Bitplane) and the results were entered
into Prism (GraphPad Software). After imaging, mice were sacrificed and
bones were processed for flow cytometry analysis.
Flow Cytometry Analysis and Apoptosis and Proliferation Assays
Flow cytometry to sort leukemic cells and assay apoptosis and proliferation
were as previously described (Gachet et al., 2013). Antibodies used are
described in Supplemental Experimental Procedures.
Statistics
We performed statistical analysis using Prism (version 5.0; GraphPad Soft-
ware). The data are expressed asmean ± SEMof n = 3 ormore determinations.
We used unpaired two-tailed Student’s t tests to analyze experimental data
between two groups, and Kaplan-Meier survival curves were compared using
the log-rank test. Differences were considered statistically significant at *p <
0.05, **p < 0.01, or ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.05.003.
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